Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification

Whereas neuroblastoma (NB) with MYCN amplification presents a poor prognosis, no single marker allows to reliably predict outcome in tumours without MYCN amplification. We report here an extensive analysis of 147 NB samples at diagnosis, without MYCN amplification, by chromosomal comparative genomic...

Descripción completa

Detalles Bibliográficos
Autores principales: Schleiermacher, G, Michon, J, Huon, I, d'Enghien, C Dubois, Klijanienko, J, Brisse, H, Ribeiro, A, Mosseri, V, Rubie, H, Munzer, C, Thomas, C, Valteau-Couanet, D, Auvrignon, A, Plantaz, D, Delattre, O, Couturier, J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Genetics and Genomics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360301/
https://www.ncbi.nlm.nih.gov/pubmed/17579628
http://dx.doi.org/10.1038/sj.bjc.6603820

Ejemplares similares

Ejemplares similares